EGFR and lung adenocarcinoma: Lung adenocarcinoma with EGFR mutations (primarily exon 19 deletions and L858R substitution in exon 21) is sensitive to targeted therapy by TKIs, such as gefitinib and erlotinib, which offers significant survival benefit to patients.